Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492972 · ClinicalTrials.gov registry record · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 4
- Study locations
NCT01492972: Recruiting Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
NCT01492972 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by Proton Collaborative Group. The registered enrollment target is 192 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492972, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by Proton Collaborative Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Primary Outcome
To determine if androgen suppression along with radiation therapy will result in a higher freedom from failure (FFF) than radiation therapy without androgen suppression. Freedom from failure (FFF): The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the current nadir PSA) (45) discounting bounces per investigator discretion, or the start of salvage th
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG Androgen Suppression Therapy
Study Locations (4)
Arizona
- Mayo Clinic - Scottsdale
Illinois
- Northwestern Medicine Chicago Proton Center - Warrenville
Oklahoma
- Oklahoma Proton Center - Oklahoma City
Virginia
- Hampton University Proton Therapy Institute - Hampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2012-01 |
| Phase | Phase 3 |
What NCT01492972 shows while recruiting
NCT01492972 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT01492972 reports a single indexed study location in Arizona, Illinois, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01492972 about?
NCT01492972 is a clinical study titled "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer". The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not...
What is the current status of trial NCT01492972?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2012-01.
What conditions does trial NCT01492972 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01492972?
The interventions under investigation include: Radiation (RADIATION), Androgen Suppression Therapy (DRUG).
Who is sponsoring clinical trial NCT01492972?
This trial is sponsored by Proton Collaborative Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01492972 being conducted?
This trial has 4 study locations across Arizona, Illinois, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01492972's enrollment target sits among peer trials
192 236th of 735 higher than 500 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
- NCT05079399 · 192 participants
Biomarker of Diabetic Retinopathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia